Citizens Financial Group Inc. RI Purchases 104,167 Shares of Pfizer Inc. (NYSE:PFE)

Citizens Financial Group Inc. RI increased its position in Pfizer Inc. (NYSE:PFE) by 52.0% during the 3rd quarter, Holdings Channel.com reports. The firm owned 304,477 shares of the biopharmaceutical company’s stock after purchasing an additional 104,167 shares during the period. Citizens Financial Group Inc. RI’s holdings in Pfizer were worth $8,812,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Olistico Wealth LLC bought a new stake in shares of Pfizer in the 2nd quarter worth approximately $25,000. MFA Wealth Advisors LLC purchased a new position in Pfizer in the 2nd quarter worth about $29,000. Gladius Capital Management LP raised its holdings in shares of Pfizer by 102.8% during the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 38,015 shares during the last quarter. Quarry LP bought a new position in shares of Pfizer during the 2nd quarter valued at $31,000. Finally, Financial Connections Group Inc. bought a new position in Pfizer in the second quarter valued at about $34,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Pfizer stock opened at $24.95 on Thursday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The company’s 50-day moving average price is $28.36 and its 200-day moving average price is $28.61. The company has a market cap of $141.36 billion, a PE ratio of 33.71, a price-to-earnings-growth ratio of 0.80 and a beta of 0.67.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.42. The business had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same period last year, the company earned ($0.17) EPS. On average, equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be issued a dividend of $0.42 per share. The ex-dividend date is Friday, November 8th. This represents a $1.68 annualized dividend and a yield of 6.73%. Pfizer’s payout ratio is 227.03%.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and increased their price target for the stock from $28.00 to $34.00 in a research report on Wednesday, August 7th. Barclays increased their price target on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Finally, Citigroup assumed coverage on Pfizer in a report on Friday, October 25th. They issued a “neutral” rating and a $30.00 price target on the stock. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.92.

Insiders Place Their Bets

In related news, Director Scott Gottlieb acquired 1,000 shares of the stock in a transaction on Wednesday, October 30th. The stock was bought at an average cost of $28.24 per share, with a total value of $28,240.00. Following the transaction, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. This represents a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. 0.06% of the stock is owned by insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.